The PROSTOX ultra test predicts late genitourinary toxicity risks in localized prostate cancer patients undergoing stereotactic body radiotherapy. Genomic testing aids in refining treatment intensity ...
LithoVue Elite system's real-time IRP monitoring may enhance flexible ureteroscopy for larger stones, offering data-driven pressure management. CVAC 2.0 ureteroscope demonstrates safety and efficacy ...
The expert faculty discuss the emerging role of circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) as biomarkers in bladder cancer, exploring their prognostic and potentially predictive ...
"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and ...
Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men. In a recent interview with Urology Times®, Mohit Khera, MD, MBA, MPH, ...
In this opening segment, the discussion focuses on the rapid evolution of kidney stone surgery and how suction has transitioned from an aspirational idea to a core component of modern ureteroscopy.
Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...
Flibanserin (Addyi) is now approved for treating HSDD in postmenopausal women, expanding its previous indication for premenopausal women. The FDA's priority review designation for flibanserin ...
Sacituzumab tirumotecan demonstrated a 31% objective response rate and 71% disease control rate in advanced urothelial carcinoma patients resistant to prior therapies. The median progression-free ...
IsoPSA test analyzes prostate cancer-specific structural variants of PSA protein to aid biopsy decisions in men over 50 with elevated PSA levels. The FDA approved IsoPSA based on a large-scale, ...
Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...
SYNC-T demonstrated high efficacy in resolving bone metastases in metastatic prostate cancer, achieving an 87% overall response rate in a phase 1 trial. The therapy involves a minimally-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback